CFOR — CapForce Share News
0.000.00%
Last trade - 00:00- $24.36m
- $23.83m
- $30.20m
Brief: Opgen Inc Entered Into A Standstill Agreement
Brief: Opgen Subsidiary Ares Genetics Successfully Maintains Key Patent Under Opposition In Europe
Brief: Opgen Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Opgen Reports First Quarter 2023 Financial Results And Provides Business Update
Brief: OpGen To Provide Q1 Financial On May 15
Brief: Opgen Announces Closing Of $3.5 Million Public Offering
Brief: Opgen Announces Pricing Of $3.5 Million Public Offering
U.S. STOCKS ON THE MOVE-OpGen, Seres Therapeutics, Wolfspeed premarket
OpGen up on completing first phase of collaboration with FIND
Brief: Opgen’S Subsidiary Curetis Meets All Remaining Key Milestones In Research And Development Collaboration With Find
U.S. STOCKS ON THE MOVE-CDW Corp, Bed Bath & Beyond, Elevance Health
U.S. STOCKS ON THE MOVE-United Airlines, Abbott Labs, Shift4 Payments
U.S. STOCKS ON THE MOVE-Tesla, Morgan Stanley, Lockheed Martin
U.S. STOCKS ON THE MOVE-Western Alliance, WeWork, Baker Hughes
OpGen Inc rises on distribution agreement for diagnostic tests
Brief: OpGen Enters Into Distribution Agreement For Unyvero In The U.S. With Fisher Healthcare
OpGen rises on seeking special clearance pathway for UTI device
Brief: Opgen Submits De Novo Request To The U.S. FDA For Unyvero Urinary Tract Infection Panel
Brief: Opgen's Subsidiary Curetis Signs Expansion Of Research And Development Collaboration With Find